Background: There is a perceived increased health risk in senior visitors t o malaria endemic countries.
As the volume of international travel increases,' there is an increase of people >60 years of age traveling to tropical countries. Few papers, however, have addressed in particular the m e d d problems and needs of senior citizens visiting malarious areas2The literature has reflected a particular concern that senior travelers could have more problems than younger travelers with antmalarial chemoprophylaxis because they often use more concomitant drugs, which could result in a higher susceptibility to adverse reactions. Age-related changes of pharmacokinetics could result in lower antimalarial blood concentrations, which could also influence effectiveness.
We decided to compare the effectiveness and tolerability of malaria chemoprophylaxis in senior travelers (260 years) with those in younger travelers (20-59 years).
An existing data set (Malpro 2)4-which consists of more than 100,000 self-administered questionnaires completed during the flight home to Europe from Africa during 1988-December 1991-was reevaluated. The population was divided into two groups: senior travelers (aged 60 years or more) and the younger age group (including travelers aged 20-59 years).These two groups were subdivided based on malaria prophylaxis into travelers who had taken mefloquine, travelers who had taken other drugs, and travelers who didn't take any chemoprophylaxis.
Results were tabulated and simple proportions were calculated for "young" and "senior" travelers.The influence of age was tested by means of multiple logistic regression (p<.05 were considered significant).
Effectiveness of malaria chemoprophylaxis in this study was determined based on whether the traveler answered " The doctor ident$ed malaria by blood-test'' and/or (in contrast to the evaluation previously p~blished)~ "The doctor concluded it was malariafrom the symptoms afmy illness." In the logistic regression model, age, sex, duration of stay in Africa, and prophylaxis were influence factors.
Tolerability to the malaria chemoprophylaxis during the traveler's stay in Africa was evaluated by the traveler's answer to the question "Have you noticed anything that you believe might be a side efect .fa drug you have been taking as prophylaxis against malaria" (therefore, instead 0f''adverse events" the term "side effect" is used in this article). In a list of side effects, the traveler could indicate "mild" "moderate" or "severe." Tolerability was also analyzed based on the traveler's answer to the question "Did you 
Results

Study Population
From the total Malpro 2 population, 84,562 questionnaires in the young age group and 9106 in the senior travelers group were included, while 5400 travelers aged 0-19 years and 1193 with missing age data were excluded. The prophylactic medication used against malaria by the study group is shown in Table 1 .
O f the senior travelers to Africa, 56.4% were Swiss, 19.3% were UK, and 4.4% were German residents.
The travelers' chemoprophylactic regimens differed as a result of varied recommendations given in different countries of residence (Table 2) .At the time of Malpro 2, mefloquine was not yet recommended in the UK; therefore, only 4.3% among young and 2.9% among senior travelers used this drug. In Switzerland and Germany, however, the respective proportions were much higher.There was no difference concerning compliance between the two age groups (Table 3) .
Senior travelers on average tended to stay longer in Africa than younger travelers: the total (proportion) of senior tourists who stayed abroad 2 weeks was 5139 (56.5%), as compared to 57,788 (68.4%) in the younger group (Fig. 1 ). For 2355 (25.996) of the senior travelers, this stay in Africa was the first visit to the tropics; in the young group, it was the first trip for 39,697 (46.9%).
Measures against mosquito bites were clearly more fiequently used by younger than by senior travelers (Fig. 2) .
Travel Associated Illness
The proportion of younger travelers who ticked the answer "I fell ill, but malaria was not suspected" was significantly higher than in the senior travelers: 13.6% compared to 7.0% (pC.05). For comparison of the subgroups and choice of possible answers, see Figure 3 .
Malaria in Africa
Eight travelers (1/1000) in the senior group reported that malaria was confirmed in Africa: in two cases based on symptoms (both were on mefloquine prophylaxis) and in six cases based on blood tests (one on mefloquine, two on chloroquine, one on proguanil, one on Fansimef, and one on chloroquine plus proguanil). In the younger population, 189 (2.2/1000) travelers reported they had malaria in Africa: 35 did not take chemoprophylaxis, 46 took mefloquine, and 108 took other drugs. Multiple logistic regression with the influence factors age, sex, duration of stay in Africa, and prophylaxis gave a significant difference for the incidence of malaria experienced in Africa between senior and younger travelers. 
Adverse Events
Of the senior travelers on mefloquine, 9.9% ticked "yes" when asked "Have you noticed anything that you believe might be a side eflect . f a drug you have been taking as prophylaxis against malaria" compared to 14.4% among younger travelers (Table 4) . O f the seniors on all other antimalarials, 10.3% ticked "yes" compared to 17.7% of the younger travelers.The significance of these dfferences was confirmed by the multiple logistic regression model. Even in the "no antimalarials taken" group, 108 of the 3363 younger travelers ticked 254 "side effects" in total, and in the senior group 13 of 450 ticked an aggregate of 17 "side effects." Figure 4 shows the rates of all the noticed side effects in the two age groups on mefloquine; Figure 5 shows the same for the travelers on all other antimalarials. The difference between senior and younger travelers on mefloquine as well as on other drugs was especially high for the side effects of nausea and dizziness.Trave1-ers on other drugs showed similar differences; in this group, the difference between younger and senior travelers was especially high for the side effects of headache and mouth ulcers.
Comedications
The influence of concomitant medication is reported in more detail elsewhere.s Briefly, 50.7% ofthe younger travelers and 44.8% of the senior travelers reported use of other drugs. As expected, elderly travelers took more cardiovascular drugs (2193/9106) compared to younger travelers (3645/84,562) but less antidiarrheals (18% vs. 28%) (Fig. 6 ).
Discussion and Conclusions
The perceived increased health risks of senior travelers who are known to have an increased rate of comorbidity and comedication is not supported by Malpro 2 data. In contrast, senior travelers tolerate malaria prophylaxis and in particular mefloquine prophylaxis at least as well as younger travelers. Surprisingly, in both age groups, travelers without chemoprophylaxis did not take more additional measures against mosquito bites compared to travelers who took antimalarials. Despite the fact that mefloquine tablets have a bitter taste, compliance was comparable to that of other drugs or even better.
The apparent well-being of the study group's senior travelers can be explained in several ways: a bias by selfselection; elderly travelers' expected preference for recreational holidays with a lower risk for illness'; and senior increased travel experience in tropical countries.
Regarding concomitant medication, younger travelers appeared to use more additional drugs than senior travelers. However, if oral contraceptives are excluded from the analysis, the number of comedications per traveler was 1.0 in the young age group and 1.3 in the senior age group. Our analysis does not confirm that drug intake in seniors is associated with an unacceptably high susceptibility to adverse drug reactions.
A recently reported pharmacokinetic study' showed that the pharmacokinetic parameters of mefloquine following a single oral dose of 250 mg in elderly subjects (age range 65-85 years) were not significantly different (p>.05) from those determined in a control group of young subjects (age range 18-27 years). Only the C,,,ax 2. value was significantly decreased by 15%.The report concluded that this decrease is assumed to be without clinical consequences, and a dose adjustment is not recommended in the elderly. However, it cannot be excluded that lower Cmaxvalues might have an influence on tolerability.
In conclusion our data support the safety of antimalarial prophylaxis in senior travelers who visit Africa.
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